Abcellera Biologics is trading at $11.60, up 4.22%, amid a broader market rebound. - No company-specific announcement explaining the November 6 move was found. The company announced a UBS conference presentation; Q3 results are scheduled for November 9. - The Nasdaq is up 1.66% and the S&P 500 is up 0.84% after the previous session’s sell-off, making the market recovery the likeliest context for the gain, not a confirmed company-specific catalyst.